Home › Funds › Frazier Life Sciences Management, L.P. › ARQT

Frazier Life Sciences Management, L.P. position in ARQT

ARCUTIS BIOTHERAPEUTICS INC · Health Care

Frazier Life Sciences Management, L.P. reported holding 9,874,511 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$258.9M, representing 5.64% of its reported portfolio and ranking #5 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed ARQT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)9.87M sh
Reported value held$258.91M
Portfolio Weight5.64%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s ARQT position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in ARQT in Q3 2023 at 8,684,232 shares (US$46.1M). The position peaked in Q4 2025 at 9,874,511 shares, worth US$286.8M. Across 12 filings, Frazier Life Sciences Management, L.P. increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 9,874,511 shares valued at US$258.9M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 8.68M $46.11M New
Q4 2023 8.76M $28.31M Add
Q1 2024 8.79M $87.06M Hold
Q2 2024 8.79M $81.70M Hold
Q3 2024 8.79M $81.70M Hold
Q4 2024 8.79M $122.38M Hold
Q1 2025 8.79M $137.40M Hold
Q2 2025 9.87M $138.44M Add
Q3 2025 9.87M $186.13M Hold
Q4 2025 9.87M $286.76M Hold
Q1 2026 9.87M $232.64M Hold
Q2 2026 9.87M $258.91M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARQT and 13F data

ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Rubric Capital Management LP (US$216.9M), ORBIMED ADVISORS LLC (US$53.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARQT

All ARQT fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held ARQT?

Frazier Life Sciences Management, L.P. has disclosed ARQT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Frazier Life Sciences Management, L.P.'s current position in ARQT?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 9.87M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $258.91M, representing 5.64% of its reported portfolio and ranking #5.

Has Frazier Life Sciences Management, L.P. been buying or selling ARQT?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in ARQT. The position peaked in Q4 2025 at 9.87M shares.

Which other funds hold ARQT?

Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Rubric Capital Management LP, ORBIMED ADVISORS LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.